Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05488873 · ClinicalTrials.gov registry record · Phase 2
A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy
A Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, sponsored by WinSanTor.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05488873 is a Phase 2 study of Chemotherapy-induced Peripheral Neuropathy that is active but no longer recruiting, run by WinSanTor. The registered enrollment target is 60 participants, below the 136-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05488873, a Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, is active but no longer recruiting, sponsored by WinSanTor.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled adaptive study of the safety, tolerability, and exploratory efficacy of once-daily topical WST-057 administered for up to 19 weeks (or up to 24 weeks for subjects who experience a chemotherapy dose delay) to subjects who are also receiving 6 cycles (3 weeks apart) of Carboplatin AUC 5-6 and Paclitaxel 175 mg/m2 (with dose adjustment per institutional guidelines permitted).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG WST-057 Active
Study Locations (1)
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-11-22 |
| Est. Completion | 2026-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05488873
The ClinicalTrials.gov registry entry for NCT05488873 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 136-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (56% lower). The listed sponsor is WinSanTor, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05488873 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05488873 about?
NCT05488873 is a clinical study titled "A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy". This is a randomized, double-blind, placebo-controlled adaptive study of the safety, tolerability, and exploratory efficacy of once-daily topical WST-057 administered for up to 19 weeks (or up to 24 weeks for subjects who experience a chemotherapy dose delay) to subjects who are also receiving 6 cyc...
What is the current status of trial NCT05488873?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-11-22. Estimated completion is 2026-05-30.
What conditions does trial NCT05488873 study?
This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy.
What interventions are being tested in trial NCT05488873?
The interventions under investigation include: Placebo (DRUG), WST-057 Active (DRUG).
Who is sponsoring clinical trial NCT05488873?
This trial is sponsored by WinSanTor, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05488873 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · Phase 2
-
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
RECRUITING · Phase 2
-
Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)
ACTIVE NOT RECRUITING · Phase 2
-
NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.